Bulletin
Investor Alert

London Markets Open in:

Market Pulse Archives

March 26, 2020, 7:58 a.m. EDT

Bristol-Myers Squibb's new MS drug is approved, launch delayed due to COVID-19

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Bristol-Myers Squibb Co. (BMY)
  • X
    Biogen Inc. (BIIB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Bristol-Myers Squibb Co. /zigman2/quotes/202559280/composite BMY -1.21% gained 1% in premarket trading on Thursday after the drugmaker said the Food and Drug Administration had approved Zeposia, its oral multiple sclerosis drug. However, the company is delaying the launch of the drug as a result of the COVID-19 outbreak, saying doing so is in the best interest of patients, customers, and employees. The drug outperformed Biogen's /zigman2/quotes/201531540/composite BIIB +4.41% Avonex in two clinical trials when examining the annualized relapse rate and the number and size of brain lesions, BMS said, and the European Medicines Agency is expected to make its decision on Zeposia in the first half of the year. A company spokesperson said the company would finalize the price of Zeposia when it is launched. Bristol-Myer's stock is down 23% year-to-date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.78% has also tumbled about 23%.

/zigman2/quotes/202559280/composite
US : U.S.: NYSE
$ 59.56
-0.73 -1.21%
Volume: 10.51M
July 8, 2020 4:00p
P/E Ratio
73.62
Dividend Yield
3.02%
Market Cap
$136.42 billion
Rev. per Employee
$968,283
loading...
/zigman2/quotes/201531540/composite
US : U.S.: Nasdaq
$ 280.19
+11.84 +4.41%
Volume: 3.26M
July 8, 2020 4:00p
P/E Ratio
8.65
Dividend Yield
N/A
Market Cap
$43.79 billion
Rev. per Employee
$1.55M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,169.94
+24.62 +0.78%
Volume: 2.39B
July 8, 2020 4:58p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.